BENGALURU (October 28): French drugmaker Sanofi SA and Britain’s GlaxoSmithKline (GSK) plan to make 200 million doses of their candidate vaccine Covid-19 available on a GAVI and World Co-led vaccine distribution plan. Health Organization (WHO).
The companies said Wednesday they had signed a statement of intent with the GAVI Vaccine Association, which coordinates the global plan known as COVAX.
COVAKS aims to deliver two billion doses of vaccine worldwide by the end of 2021, and more than 180 nations have joined the plan.
The United States and Britain are in a hurry to bargain with drug manufacturers to stockpile experimental coronavirus vaccines.
GSK-Sanofi has currently signed a $ 2.1 billion deal with the United States to provide more than 100 million doses of its coronavirus vaccine candidate. The companies also have deals with the European Union and the UK.
The first results of the early study of the mid-stage Sanofi-GSK vaccine are expected in early December 2020, and the companies plan to submit regulatory approval in 2021.
The vaccine candidate uses the same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines. E be in combination with an adjuvant, a substance that acts as a booster of the vaccine, made by GSK.
The level of protection and timing of early Covid-19 vaccines are still uncertain, says British minister